Prof Jack Cuzick speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the preventative effects of anastrozole in post-menopausal, high-risk women.
He explains the rationale behind this study, which has achieved a 60 percent reduction of breast cancer incidence in the first five years and an additional 36 percent after every subsequent year.
Prof Cuzick also notes that this long-term follow up shows the effectiveness of anastrozole over tamoxifen.
He also discusses how patients were stratified as "high-risk", associated adverse effects and the possibility of investigating mortality in the future.
Watch the press conference here.
Read more about the study here.